Aldeyra Therapeutics (DE:137)

NASDAQ:137

137

Aldeyra Therapeutics

RESEARCH TOOLSreports

Aldeyra Therapeutics (137) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

137 Analyst Ratings

Moderate Buy

1 Buy

1 Hold

0 Sell

Based on 2 analysts giving stock ratings to

Aldeyra

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

137 Stock 12 Month Forecast

Average Price Target

€4.73

▲(211.08% Upside)

Based on 2 Wall Street analysts offering 12 month price targets for Aldeyra Therapeutics in the last 3 months. The average price target is €4.73 with a high forecast of €7.74 and a low forecast of €1.72. The average price target represents a 211.08% change from the last price of €1.52.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","2":"€2","4":"€4","6":"€6","8":"€8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.73730972,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€7.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.72835594,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€4.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.71940216,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.72</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.41,1.8967161323076922,2.3834322646153847,2.870148396923077,3.3568645292307693,3.8435806615384616,4.330296793846154,4.817012926153846,5.303729058461538,5.790445190769231,6.277161323076923,6.763877455384615,7.2505935876923076,{"y":7.73730972,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.41,1.6652581492307692,1.9205162984615383,2.1757744476923078,2.431032596923077,2.686290746153846,2.9415488953846154,3.1968070446153845,3.4520651938461535,3.707323343076923,3.9625814923076925,4.217839641538461,4.473097790769231,{"y":4.72835594,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.41,1.433800166153846,1.4576003323076923,1.4814004984615383,1.5052006646153846,1.5290008307692307,1.552800996923077,1.576601163076923,1.6004013292307693,1.6242014953846153,1.6480016615384616,1.6718018276923077,1.6956019938461537,{"y":1.71940216,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.851,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.199,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.052,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.906,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.446,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.366,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.459,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.321,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.561,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.777,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.444,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€7.74

Average Price Target€4.73

Lowest Price Target€1.72

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matthew Caufield

H.C. Wainwright

€1.72

Hold

13.12%

Upside

Reiterated

05/11/26

Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (NASDAQ: ELVN), Molina Healthcare (NYSE: MOH) and Aldeyra Therapeutics (NASDAQ: ALDX)

Thomas Shrader

BTIG

€7.74

Buy

409.03%

Upside

Reiterated

03/17/26

Analysts Are Bullish on These Healthcare Stocks: Healthequity (HQY), Kestra Medical Technologies Ltd. (KMTS)

Clara Dong

Jefferies

€6.02

Buy

295.91%

Upside

Reiterated

10/08/25

Promising Developments and Strategic Partnerships Drive Buy Rating for Aldeyra Therapeutics

Marc Goodman

Leerink Partners

€8.6

Buy

465.59%

Upside

Reiterated

08/12/25

Aldeyra Therapeutics: Positive NDA Resubmission and Strategic Advancements Support Buy Rating

Catherine Novack

JonesTrading

€5.16→€7.74

Buy

409.03%

Upside

Reiterated

08/08/25

Aldeyra Therapeutics (ALDX) Receives a Buy from JonesTrading

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matthew Caufield

H.C. Wainwright

€1.72

Hold

13.12%

Upside

Reiterated

05/11/26

Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (NASDAQ: ELVN), Molina Healthcare (NYSE: MOH) and Aldeyra Therapeutics (NASDAQ: ALDX)

Thomas Shrader

BTIG

€7.74

Buy

409.03%

Upside

Reiterated

03/17/26

Analysts Are Bullish on These Healthcare Stocks: Healthequity (HQY), Kestra Medical Technologies Ltd. (KMTS)

Clara Dong

Jefferies

€6.02

Buy

295.91%

Upside

Reiterated

10/08/25

Promising Developments and Strategic Partnerships Drive Buy Rating for Aldeyra Therapeutics

Marc Goodman

Leerink Partners

€8.6

Buy

465.59%

Upside

Reiterated

08/12/25

Aldeyra Therapeutics: Positive NDA Resubmission and Strategic Advancements Support Buy Rating

Catherine Novack

JonesTrading

€5.16→€7.74

Buy

409.03%

Upside

Reiterated

08/08/25

Aldeyra Therapeutics (ALDX) Receives a Buy from JonesTrading

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Aldeyra Therapeutics

3 Months

Marc GoodmanLeerink Partners

Success Rate

15/25 ratings generated profit

Average Return

+21.34%

Copying Marc Goodman's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +21.34% per trade.

1 Year

Catherine NovackJonesTrading

Success Rate

8/14 ratings generated profit

Average Return

+17.61%

Copying Catherine Novack's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +17.61% per trade.

2 Years

Marc GoodmanLeerink Partners

Success Rate

8/25 ratings generated profit

Average Return

-15.82%

Copying Marc Goodman's trades and holding each position for 2 Years would result in 32.00% of your transactions generating a profit, with an average return of -15.82% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

137 Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 137 has received 0 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 137 average Analyst price target in the past 3 months is 4.73.

Each month's total comprises the sum of three months' worth of ratings.

137 Financial Forecast

137 Earnings Forecast

Next quarter’s earnings estimate for 137 is -€0.09 with a range of -€0.14 to -€0.05. The previous quarter’s EPS was -€0.05. 137 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 137 has Performed in-line its overall industry.

No data currently available

137 Sales Forecast

Next quarter’s sales forecast for 137 is €26.87M with a range of €0.00 to €80.62M. The previous quarter’s sales results were €0.00. 137 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 137 has Performed in-line its overall industry.

137 Stock Forecast FAQ

What is DE:137’s average 12-month price target, according to analysts?

Based on analyst ratings, Aldeyra Therapeutics’s 12-month average price target is 4.73.

What is DE:137’s upside potential, based on the analysts’ average price target?

Aldeyra Therapeutics has 211.08% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Aldeyra Therapeutics a Buy, Sell or Hold?

Aldeyra Therapeutics has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.

What is Aldeyra Therapeutics’s share price target?

The average share price target for Aldeyra Therapeutics is 4.73. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €7.74 ,and the lowest forecast is €1.72. The average share price target represents 211.08% Increase from the current price of €1.52.

What do analysts say about Aldeyra Therapeutics?

Aldeyra Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of Aldeyra Therapeutics?

To buy shares of DE:137, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Aldeyra Therapeutics (137) Stock Forecast & Price Target

137 Analyst Ratings

137 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Aldeyra Therapeutics

137 Analyst Recommendation Trends

137 Financial Forecast

137 Earnings Forecast

137 Sales Forecast

137 Stock Forecast FAQ

Detailed List of Analyst Forecasts